Category survey

Implicating Novel Genes in Familial Parkinsonism Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Brain degeneration and regeneration in preclinical models of Alzheimer’s disease Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Structural Studies of Parkinson’s Disease Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Diagnostic Biomarkers for pre-dementia Alzheimer Disease Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Investigation of the roles of GSK-3 isoforms in mediating Abeta, tau and insulin related Alzheimer-like synaptic, cholinergic impairments Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Enhancing vascular remodeling in Alzheimer’s disease following covert stroke Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Quantitative MR Imaging of Vascular Contributions to Aging, Cognitive Decline and Stroke Investments > €500k Canada Neurodegenerative disease in general 2016    

Mutational and Functional Analysis of Genes Identified by GWAS Studies of Alzheimer’s Disease Investments > €500k Canada Neurodegenerative disease in general 2016    

Clinical, Pathological, Genetic and Biomarker Studies of Frontotemporal Dementia Investments > €500k Canada Neurodegenerative disease in general 2016    

Typical and atypical Alzheimer Disease: salivary tau biomarkers, therapy with neuromodulation, and disease subtypes. Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Functional Neuroimaging of dopamine systems: application to Parkinson’s Disease, addiction and obesity. Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Aberrant NMDA receptor and synaptic signaling in vulnerability to neurodegeneration: Focus on Huntington disease Investments > €500k Canada Huntington’s disease 2016    

Insights into Parkinson’s disease, Crohn’s disease, and leprosy: a common role for LRRK2 Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Canadian Consortium on Neurodegeneration in Aging – Full Proposal Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Virtual Reality based Spatial Memory Intervention for patients with Mild Cognitive Impairment Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Cohort to illuminate Neurodegeneration, Genetics, Imaging Associations and Leukoaraiosis (CONGENIAL) Investments > €500k Canada Neurodegenerative disease in general 2016    

Genetic Frontotemporal Dementia Initiative (GENFI) in Canada Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Role of PINK1 Processing in Mitochondrial Function and Parkinson’s Disease Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Neurovascular Adaptation Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Investigation of the bioeffects of blood-brain barrier disruption by focused ultrasound: A multifaceted imaging approach Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Aberrant phospholipid and sphingolipid metabolism is a primary and targetable pathology in Alzheimer Disease Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Towards a better understanding of the language impairment and neural basis of primary progressive aphasia: A longitudinal study Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Role of translational mechanisms in the retrograde regulation of Synaptic homeostasis Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Novel approaches to modulate key targets in the pathogenesis of Huntington Disease Investments > €500k Canada Huntington’s disease 2016    

Cellular lipids in Huntington’s disease Investments > €500k Canada Huntington’s disease 2016    

Studies on the plasticity of CNS cholinergic neurons Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Investigating the mechanism of Amyloid-beta GxxxG-motif-targeting agents Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Magnetic resonance imaging biomarkers in ALS Investments > €500k Canada Motor neurone diseases 2016    

Potentiels thérapeutiques de la cystamine pour la maladie de Parkinson. Potential therapeutic cystamine for Parkinson’s disease. Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Cathepsin D Activation: A Target to Reduce Alpha-Synuclein Pathology in a Parkinson’s Model Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Deciphering Protein Quality Control Pathways Targeting Cytosolic Proteins for Proteasome Degradation Investments > €500k Canada Neurodegenerative disease in general 2016    

Molecular and Biological Characterisation of Novel Genetic Markers Associated to the Common of Alzheimer’s Disease in a Population Isolate from Eastern Canada Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Effects of aerobic exercise on cognition and brain health in older adults at increased risk of Alzheimer disease and dementia: probing the biological mechanisms using translational physiology. Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Elucidating the Protective Mechanism of Phospho-N17 Huntingtin in Huntington’s disease Investments > €500k Canada Huntington’s disease 2016    

Regulation of neuronal resilience in Alzheimer’s disease by the STI1/Prion protein complex Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Exploring cholinergic mechanisms to understand behavioral deficits in dementia. Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

The role of RCAN1 in Alzheimer pathogenesis Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

REGULATION OF THE STRESS GRANULE PROTEOME AND TRANSCRIPTOME BY TDP-43 IN ALS: BIOMARKERS AND THERAPEUTIC TARGETS Investments > €500k Canada Motor neurone diseases 2016    

Propagated protein misfolding of SOD1 in ALS: Exemplar for neurodegeneration. Investments > €500k Canada Motor neurone diseases 2016    

Validation of ocular measures as potential biomarkers for early detection of brain amyloid and neurodegeneration. Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Prevention of Alzheimer’s Dementia in High Risk Populations: A Randomized Controlled Trial of a Combination of Cognitive Remediation and Brain Stimulation Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Modulating memory circuits: focal DBS treatments to improve medial temporal lobe function Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Locally produced brain insulin in memory and Alzheimer’s disease: A multi-disciplinary approach to a key question Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Targeting Amyloid Propagation in Alzheimer Disease: Structures, Immunology and Extracellular Vesicle Topology Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Validation of Connexins and Pannexins as a target for Alzheimer’s Disease Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Novel Retinal Biomarkers for Alzheimer’s Disease Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Preclincal development of a disease modifying small molecule therapy for Alzheimer diease. Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Novel blood and neuroimaging markers of Alzheimer’s disease and cerebral amyloid angiopathy Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Reshaping Mitochondrial Efficiency and Integrity to Treat Parkinson’s Disease Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

CBRAIN: Canadian Brain Research And Informatics Platform Investments > €500k Canada Neurodegenerative disease in general 2016